Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations

(2020) Mayu Kawasaki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report

(2020) Chie Iitake et al.   Cardiovascular Diabetology

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

(2019) Koutaro Yokote et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Efficacy and Safety of Pemafibrate in Patients with Type 2 Diabetes and Elevated Triglyceride levels: 52-Week Data From The PROVIDE Study

(2019) Eiichi Araki et al.   DIABETES OBESITY & METABOLISM

A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21

(2019) Steven A. Kliewer et al.   Cell Metabolism

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis

(2019) Satoshi Ida et al.   Cardiovascular Diabetology

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

(2019) Jean-Charles Fruchart et al.   Cardiovascular Diabetology

The FGF metabolic axis

(2019) Xiaokun Li   Frontiers of Medicine

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

(2019) Yamashita et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα

(2018) Yuta Yamamoto et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

(2018) Eiichi Araki et al.   DIABETES CARE

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

(2018) Hidenori Arai et al.   Journal of Atherosclerosis and Thrombosis

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

(2018) Shun Ishibashi et al.   Journal of Clinical Lipidology

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

(2018) Christophe Corpechot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials

(2018) Luis E. Simental-Mendía et al.   PHARMACOLOGICAL RESEARCH

Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

(2018) Ikuro Matsuba et al.   Journal of Diabetes Investigation

Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells

(2018) Tao Dong et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice

(2018) Masaya Araki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review

(2017) Duminda Suraweera et al.   LIVER INTERNATIONAL

Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway

(2017) Toshinobu Maki et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis

(2017) Yasushi Honda et al.   Scientific Reports

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

(2016) Shun Ishibashi et al.   ATHEROSCLEROSIS

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

(2016) Giovanni Targher et al.   JOURNAL OF HEPATOLOGY

Non-alcoholic fatty liver disease and dyslipidemia: An update

(2016) Niki Katsiki et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathophysiology of diabetic dyslipidaemia: where are we?

(2015) Bruno Vergès   DIABETOLOGIA

Fibrates and cholestasis

(2015) Nisanne S. Ghonem et al.   HEPATOLOGY

Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver

(2015) Sana Raza-Iqbal et al.   Journal of Atherosclerosis and Thrombosis

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies

(2014) Setor K. Kunutsor et al.   ATHEROSCLEROSIS

Utility of the Triglyceride Level for Predicting Incident Diabetes Mellitus According to the Fasting Status and Body Mass Index Category: The Ibaraki Prefectural Health Study

(2014) Kazuya Fujihara et al.   Journal of Atherosclerosis and Thrombosis

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

(2013) Gregory Gaich et al.   Cell Metabolism

Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study

(2012) Yuichiro Eguchi et al.   JOURNAL OF GASTROENTEROLOGY

Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome

(2010) Renata Belfort et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES